GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

Additionally, the expected growth in outpatient dosing and the expansion of Carvykti’s use in earlier treatment lines are seen as positive indicators. These factors, coupled with the anticipated ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Switzerland is the fifth country where CARVYKTI is now commercially available to patients along with United States, Germany, ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of multiple myeloma, providing promising data from the Phase 3 CARTITUDE-4 trial. Their CARVYKTI therapy ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T ...

to fulfill CARVYKTI’s potential to transform the treatment paradigm for multiple myeloma.” Mr. Bash earned his B.A. from Georgetown University and his M.B.A. from Columbia Business School.

Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with CARVYKTI ®. Do not administer CARVYKTI ® to patients with active ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T) therapy has ...